TIDMFARN
RNS Number : 4823W
Faron Pharmaceuticals Oy
23 April 2021
Faron Pharmaceuticals Oy
("Faron" or the "Company")
Board Change
Company announcement, 23 April 2021 at 15:45 EET
TURKU, FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First
North: FARON), the clinical stage biopharmaceutical company, is
pleased to announce the appointment of Anne Whitaker as a
Non-Executive Director of the Company following the passing of all
resolutions put to shareholders of the Company at the AGM held
earlier today.
Anne has more than 25 years of experience in the life science
industry, including senior leadership roles with large
pharmaceutical, biotech and speciality pharma companies. She is the
current Chairman of the Board for Aerami Therapeutics Holdings,
Inc. (formerly Dance Biopharm Holdings, Inc.), a private life
science company . Prior to taking the role of Chairman at Aerami,
Anne served as the Company's Chief Executive Officer and a Director
from October 2018 to November 2020. Anne served as Chief Executive
Officer of Novoclem Therapeutics, Inc . from February 2017 until
April 2018. Prior to that, she served as Executive Vice President
at Bausch Health overseeing its Global Branded Pharmaceutical
Business and the Western European Region from May 2015 to January
2017. Previously , Anne served as President and Chief Executive
Officer of Synta Pharmaceuticals. She also served as President,
North America Pharmaceuticals at Sanofi, where she oversaw all
pharmaceutical and consumer healthcare operations for the region
and held several commercial leadership roles at
GlaxoSmithKline.
Additional Disclosures
The following information regarding the appointment of Anne
Michelle Clem Whitaker, aged 53, is disclosed under Schedule 2(g)
of the AIM Rules for Companies:
Current directorships and/or Former directorships and/or partnerships
partnerships: (within the last five years):
Aerami Therapeutics, Inc. Chason Dreams, LLC
Anne Whitaker Group, LLC Cree, Inc.
Caladrius Biosciences, Inc. Novoclem Therapeutics, Inc.
Mallinckrodt plc* Vectura Group plc
UDG Healthcare plc
Ms Whitaker does not have any beneficial interest in the
ordinary shares of the Company.
*Mallinckrodt plc has recently filed for bankruptcy while facing
class action litigation.
Save as set out above, no further information regarding Anne
Whitaker is required to be disclosed pursuant to Schedule Two,
paragraph (g) of the AIM Rules for Companies.
For more information please contact:
Faron Pharmaceuticals Oy
Dr Markku Jalkanen, Chief Executive Officer
investor.relations@faron.com
Cairn Financial Advisers LLP, Nomad
Sandy Jamieson, Jo Turner, Mark Rogers
Phone: +44 207 213 0880
Peel Hunt LLP, Broker
Christopher Golden, James Steel
Phone: +44 (0) 20 7418 8900
Sisu Partners Oy, Certified Adviser on Nasdaq First North
Juha Karttunen
Phone: +358 (0)40 555 4727
Jukka Järvelä
Phone: +358 (0)50 553 8990
Consilium Strategic Communications
Mary-Jane Elliott, David Daley, Lindsey Neville
Phone: +44 (0)20 3709 5700
Email: faron@consilium-comms.com
Stern Investor Relations
Julie Seidel, Alexa Comai
Phone: +1 (212) 362-1200
E-mail: julie.seidel@sternir.com
About Faron Pharmaceuticals Oy
Faron (AIM: FARN, First North: FARON) is a clinical stage
biopharmaceutical company developing novel treatments for medical
conditions with significant unmet needs caused by dysfunction of
our immune system. The Company currently has a pipeline based on
the receptors involved in regulation of immune response in
oncology, organ damage and bone marrow regeneration. Bexmarilimab,
a novel anti-Clever-1 humanised antibody, is its investigative
precision immunotherapy with the potential to provide permanent
immune stimulation for difficult-to-treat cancers through targeting
myeloid function. Currently in Phase I/II clinical development as a
potential therapy for patients with untreatable solid tumours,
bexmarilimab has potential as a single-agent therapy or in
combination with other standard treatments including immune
checkpoint molecules. Traumakine(R) is an investigational
intravenous (IV) interferon beta-1a therapy for the treatment of
acute respiratory distress syndrome (ARDS) and other ischemic or
hyperinflammatory conditions. Traumakine(R) is currently being
evaluated in global trials as a potential treatment for
hospitalised patients with COVID-19 and with the 59th Medical Wing
of the US Air Force and the US Department of Defense for the
prevention of multiple organ dysfunction syndrome (MODS) after
ischemia-reperfusion injury caused by a major trauma. Faron is
based in Turku, Finland. Further information is available at
www.faron.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAPPUUWCUPGGPW
(END) Dow Jones Newswires
April 23, 2021 08:45 ET (12:45 GMT)
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Apr 2024 to May 2024
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From May 2023 to May 2024